SOVREMENNOE PREDSTAVLENIE O FENOTIPAKh BRONKhIAL'NOY ASTMY


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

More than half of patients with persistent bronchial asthma (BA) do not have control of the disease, despite the progress in pharmacotherapy. Modern management of BA requires the development of targeted treatments with account of clinical and biological phenotypes of the disease. Identification of BA phenotypes is performed on the basis of clinical and biological parameters and cluster analysis, and allows to identify five clusters of BA in adults, differing in clinical course, intensity and type of inflammation. Bio- or inflammatory phenotypes of BA reflect the type of respiratory tract inflammation: eosinophilic and non-eosinophilic. Allergen-specific immunotherapy and anti-IgE-therapy (omalizumab) are currently available types of phenotype-specific treatment of BA.

Толық мәтін

Рұқсат жабық

Авторлар туралы

N. Nenasheva

Әдебиет тізімі

  1. GINA, 2011. www.ginasthma.com
  2. Demoly P1 Gueron B, Annunziata K, et al. Update on asthma control in five European countries: results of a 2008 survey. Eur Respir Rev 2010;116:150-5I.
  3. Rackemann FM. A clinical classification of asthma. Am J Med Sci 1921 ;12:802-3.
  4. Адо А.Д., Булатов П.К. Клинико-физиологические основы классификации бронхиальной астмы. В кн.: Материалы к V межобластной научной конференции терапевтов. Этиология, патогенез, клиника и лечение заболеваний органов дыхания / Под ред. П.К. Булатова. Ленинград, 1969. С. 258-65.
  5. Turner-Warwick M. On observing patterns of airflow obstruction in chronic asthma. Br J Dis Chest 1911;11:13-86.
  6. Федосеев Г.Б. Современное представление о причинах возникновения, особенностях течения и лечения бронхиальной астмы. Актовая речь. Ленинград, 1982. 28 с.
  7. Wenzel S. Asthma: defining of the persistent adult phenotypes. Lancet 2006;368:804-13.
  8. Johansson SG, Hourihane JO, Bousquet J, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001 ;56(9):813-24.
  9. Haldar P, Pavord I, Shaw D, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;118:218-24.
  10. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010181:315-23.
  11. Simpson JL, Scott R, Boyle MJ, et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006;11:54-61.
  12. Nasser SM, Pfister R, Christie PE, et al. Inflammatory cell populations in bronchial biopsies from aspirinsensitive asthmatic subjects. Am J Respir Crit Care Med 1996;153:90-96.
  13. Frew Al, Chan H, Lam S, Chan-Yeung M. Bronchial inflammation in occupational asthma due to western red cedar. Am J Respir Crit Care Med 1995;151:340-44.
  14. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1115-21.
  15. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 21:483-94.
  16. Simpson JL, Scott RJ, Boyle MJ, et al. Differential Proteolytic Enzyme Activity in Eosinophilic and Neutrophilic Asthma. Am J Respir Crit Care Med 2005;112:559-65.
  17. Cundall M, Sun Y, Miranda C, et al. Neutrophil-derived matrix metalloproteinase-9 is increased in severe asthma and poorly inhibited by glucocorticoids. J Allergy Clin Immunol 2003; 112:1064-11.
  18. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of a subgroup with isolated sputum neutrophilia and pore response to inhaled corticosteroids. Thorax 2002;51:815-19.
  19. Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and noneosinophilic asthma. Thorax 2001;62:1043-49.
  20. Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 1995; 154;4119-25.
  21. Nguyen LT, Lin S, Oates T, Chung KF. Increase in airway neutrophilia after oral but not inhaled corticosteroid therapy in mild asthma. Respir Med 2005;99:200-1.
  22. Green RH, Pavord I Stability of inflammatory phenotypes in asthma. Thorax 2012. Online First, published on April 21 as 10.1136/thoraxjnl-2012-201651.
  23. Abramson MJ: Allergen immunotherapy in asthma. Cochrane Database Syst Rev 2003;4:CD001186.
  24. Calamita Z, Saconato H, et al. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006;61:1162-12.
  25. Chung KF, Bel EH, Wenzel SE. Difficult-to-Treat Severe Asthma. European Respiratory Society Monograph 2011;51,310 p.
  26. Walter S, Monteil M, Phelan K et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006;2:CD003559.
  27. Rodrigo GJ, Neffen H, Castro-Rodriques JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-jn-therapy to corticosteroids to children and adults with asthma: systemic review. Chest 2011;139:28-35.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2013

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>